Literature DB >> 16122442

Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy.

Kenji Minakata1, Joseph A Dearani, Hartzell V Schaff, Patrick W O'Leary, Steve R Ommen, Gordon K Danielson.   

Abstract

BACKGROUND: Left ventricular septal myectomy provides excellent outcomes for symptomatic patients with severe obstructive hypertrophic cardiomyopathy. However, in a few patients, left ventricular outflow tract obstruction may recur and require repeat myectomy. We reviewed this subset of patients to assess the mechanisms of recurrence.
METHODS: From 1975 to July 2003, 610 septal myectomies were performed; 13 of these were repeat myectomies after classic myectomies performed at our institution (n = 6) or elsewhere (n = 7). Ages ranged from 4 to 70 years (mean, 32 +/- 22). The interval between initial myectomy and repeat myectomy ranged from 13 months to 11 years (mean, 5.0 +/- 3.7 years).
RESULTS: Mechanisms for obstruction included limited myectomy at the initial myectomy (n = 11), septal hypertrophy at the midventricular level (n = 8), and anomalous papillary muscles (n = 3). Mean intraoperative pressure gradients decreased from 82 +/- 24 to 6.2 +/- 4.4 mm Hg. No mitral valve replacement was performed, and there were no early deaths. Mean follow-up was 5.8 +/- 5.8 years. There was one late death. All surviving patients were free from recurrence of outflow tract obstruction and were in the New York Heart Association functional class I or II.
CONCLUSIONS: Mechanisms for recurrent obstruction included limited myectomy at the initial operation, midventricular obstruction, anomalies of papillary muscles, and ventricular remodeling, especially in pediatric patients. Repeat myectomy can be performed with excellent outcomes. Need for reoperation may be reduced with current surgical approaches that include a more extended resection of the midventricular septum, relief of papillary muscle anomalies, and routine use of intraoperative transesophageal echocardiography.

Entities:  

Mesh:

Year:  2005        PMID: 16122442     DOI: 10.1016/j.athoracsur.2005.03.108

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

Review 1.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

2.  Surgical treatment for obstructive hypertrophic cardiomyopathy.

Authors:  Kenji Minakata; Ryuzo Sakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-05-28

3.  Extended Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy in Children and Adolescents.

Authors:  Haitao Xu; Jun Yan; Qiang Wang; Dianyuan Li; Hongwei Guo; Shoujun Li; Ju Wang; Song Lou; Qingdong Zeng
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

4.  Surgery for hypertrophic cardiomyopathy.

Authors:  James J Wu; Michael Seco; Caroline Medi; Chris Semsarian; David R Richmond; Joseph A Dearani; Hartzell V Schaff; Michael J Byrom; Paul G Bannon
Journal:  Biophys Rev       Date:  2015-01-10

5.  Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.

Authors:  Kunal D Kotkar; Sameh M Said; Joseph A Dearani; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

6.  Mitral valve replacement and septal myectomy for hypertrophic obstructive cardiomyopathy.

Authors:  Kouji Furukawa; Takahiro Hayase; Mitsuhiro Yano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-02

7.  Surgical outcomes and strategy of hypertrophic obstructive cardiomyopathy.

Authors:  Ya-bin Zhu; S Rajan; V M Kurian; Zhi-yong Liu
Journal:  J Zhejiang Univ Sci B       Date:  2006-02       Impact factor: 3.066

8.  Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective.

Authors:  Edward K Rhee; John J Nigro; Stephen G Pophal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

9.  Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy.

Authors:  Lothar Faber; Dirk Welge; Detlef Hering; Thomas Butz; Olaf Oldenburg; Hubert Seggewiss; Dieter Horstkotte
Journal:  Clin Res Cardiol       Date:  2008-09-05       Impact factor: 5.460

Review 10.  Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Authors:  C Charles Jain; Darrell B Newman; Jeffrey B Geske
Journal:  Curr Cardiol Rep       Date:  2019-10-31       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.